AstraZeneca has recently provided an update on its Immuno-Oncology (IO) late-stage clinical development programme in 1st-line non-small cell lung cancer (NSCLC), including a refinement of the phase III Mystic trial.
The Mystic trial was initially designed to assess the benefit of durvalumab monotherapy and durvalumab and tremelimumab (durva + treme) combination therapy versus standard-of-care (SoC) chemotherapy, focused on progression-free survival (PFS). The Mystic trial will now assess PFS and overall survival (OS) endpoints in patients with PDL1-expressing tumours for both durvalumab monotherapy and the combination of durva + treme, as well as in ‘all comers’ for the combination of durva + treme, versus SoC chemotherapy.
While the focus remains on exploring the benefit of durva + treme as combination therapy, the company has updated the endpoints of the Mystic trial to include OS and PFS in durvalumab monotherapy. This is based on recent internal and external data, including durvalumab’s strong efficacy in monotherapy presented at recent medical meetings, as well as significant opportunities in the competitive landscape.
The estimated primary completion date has been updated to reflect both an increase in patient recruitment (as reported in February 2016 with the inclusion of OS as a coprimary endpoint) and the event-based nature of the trial. As a result, the company anticipates Mystic PFS data in mid-2017 and final OS data at the latest in 2018. Mystic also includes several undisclosed interim analyses for OS.
Additionally, the ongoing phase III Neptune trial will be expanded with local patients to support regulatory submission of durva + treme combination therapy in China for 1st-line NSCLC patients without delaying the anticipated OS data readout in 2018 from the global cohort, which is approaching full recruitment. The company has also initiated the new phase III Pearl trial of durvalumab monotherapy versus SoC chemotherapy in 1st-line NSCLC patients whose tumours express PD-L1. The Pearl trial focuses on Asian countries, primarily China, due to the high prevalence of NSCLC in the region.
Sean Bohen, executive vice president, global medicines development and chief medical officer at AstraZeneca, says “The Mystic trial amendments, the Neptune trial expansion and initiation of the new Pearl trial are all designed to enhance our options in 1st-line NSCLC for IO-IO combination as well as for IO monotherapy. We continue to follow the science through both internal and external sources for the benefit of patients and look forward to sharing our first pivotal data in mid-2017
